Depression (neuro) Flashcards

1
Q

Characteristics of affective disorders

A

Characteristics of Affective Disorders
– Disorders of mood rather than thought / cognition
– Most common is depression
– Major cause of premature death and disability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Unipolar depression

A
1) Unipolar Depression
– Mood swings in one direction
– Most common depressive illness
– 75% cases REACTIVE (induced by environmental factors)
– 25% cases ENDOGENOUS (genetic)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Bipolar depression

A
1) Unipolar Depression
– Mood swings in one direction
– Most common depressive illness
– 75% cases REACTIVE (induced by environmental factors)
– 25% cases ENDOGENOUS (genetic)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Symptoms of depression

A
  • Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure.
  • Note: Do note include symptoms that are clearly due to a general medical condition, or mood-incongruent delusions or hallucinations.
    1) Depressed mood most of the day, nearly every day (in children irritable mood)
    2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
    3) Significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day.
    4) A slowing down of thought and a reduction of physical movement (observable by others, not merely subjective feelings of restlessness or being slowed down).
    5) Fatigue or loss of energy nearly every day.
    6) Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
    7) Diminished ability to think or concentrate, or indecisiveness, nearly every day.
    8) Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Symptomology: ICD-10

A
- Emotional symptoms (Q):
• Apathy, pessimism, negativity
• Low self esteem, feeling guilty
• Loss of motivation
• Indecisiveness
- Biological symptoms (Q):
• Reduced activity
• Loss of libido
• Sleep disturbance
• Loss of appetite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Co-morbidity

A
General medical conditions in which you often find 
depression:
- Terminal illness
- Chronic illness (e.g. chronic pain)
- Thyroid dysfunction
- Neurological disease
- Stroke
- Drug abuse
- Parkinson’s disease
- anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Monamine Theory

A

Evidence For:
- Overall reduced activity of central noradrenergic and/ or serotonergic systems
- Reserpine depletes brain of NA and 5-HT induces depression
- Main antidepressant drugs increase [amines] in brain (Q devise drugs to treat depression)
Evidence Against:
- Difficult to show deficits in brain [NA] & [5-HT] and functioning/ (-) results from CSF, plasma in depressed /individuals respond better to one AD than another
- Most antidepressant drugs take several weeks for therapeutic effect but  in amines acute (secondary adaptive changes more important)
- Some antidepressants weak / no effect on amine uptake (e.g trazodone)/no increase in 5HT and NA but antidepressants!
- Cocaine blocks amine uptake but has no. antidepressant effect
- Decrease in 5HT in dipolar linked to aggression rather than depression
- Due to imbalances between NT (Monoamines, DA, Ach, CRF, CORT ect) producing long term alterations in gene expression, growth factors and NT (upregulation 5HT, NA receptors, HPA hyperfunction and some neuronal loss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Neuroendocrine Theory

A
  • NAergic & 5-HT neurons input to
    hypothalamus
  • Hypothalamus releases corticotropin-releasing hormone (CRH)
  • CRH acts on pituitary – release of adrenocorticotrophic hormone (ACTH)
  • Cortisol release from adrenal cortex in response to increased ACTH in blood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Neuroendocrine

A
  • CRH - behavioural effects mimic some depression symptoms
  • Evidence of hyperactivity of HPA in depressed patients
    • increased [cortisol]plama in depressed patients
    • increased [CRH] in the cerebrospinal fluid
  • There is clear evidence that genes and environment can contribute to this hyperactivity and as such could offer an explanation for how genes x environment interaction can predispose people to mental health conditions (diathesis)
  • decreased hippocampal feedback in depression
  • decreased glucocorticoid receptors (cortisol receptors) in hippocampus
  • Glucocorticoid receptor gene expression regulated by early experience
  • Tactile stimulation just after birth activates 5-HT pathways to hippocampus
  • 5-HT triggers long-lasting  in expression of glucocorticoid receptor gene
  • increased in glucocorticoid receptors in hippocampus
    •SSRIs increased glucocorticoid receptors in the hippocampus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Neuroplasticity and Neurogenesis

A
  • Evidence of neuronal loss and  neuronal activity in
    hippocampus and prefrontal cortex (decision making centres)
  • Antidepressants and electroconvulsive therapy (ECT) promote neurogenesis in these regions
  • 5-HT promotes neurogenesis during development (BDNF)
  • Increase in Glutamate in Cx of depressed people (NMDA antagonists potential for depression treatment e.g. ketamine)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Psychological treatment

A
  • Cognitive Behavioural Therapy: based on helping depressed individuals to recognise and change their negative cognitive processes and thus improve their mood and their counterproductive behaviours
  • Interpersonal Therapy: assumes that depression is multi-factorial but that interpersonal difficulties play a central role in maintaining depressive symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pharmacological treatment

A
  • Tricyclic antidepressants
    • Monoamine oxidase inhibitors
    • Selective serotonin reuptake inhibitors
  • NICE recommends SSRIs for the pharmacological treatment of depression
  • Selectively inhibit the reuptake of serotonin in the synapse
  • Because they are more selective in the molecules to which they bind, they do not bind to receptors on other classes of neurons (fewer side effects)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Long term neurochemical effects of AD

A
  • Monoamine Oxidase Inhibitors (MAOIs)
  • Tricyclic Antidepressant Drugs (TCAs)
  • Selective Serotonin Re-uptake Inhibitors (SSRIs)
  • Other mixed 5HT/NA reuptake inhibitors (SNRIs)
  • NA reuptake inhibitors
  • Monoamine receptor antagonists (alpha2, 5HT2c, 5HT3)
  • Downregulation alpha2, 5HT1A, beta1, beta2, 5HT2A, 5HT3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MAOIs

A
  • Inhibition of MAO A correlates with AD activity
  • MAO-A 5-HT > NA (Q. what about MAOB?)
  • MAOIs rapidly increased [5-HT] > [NA] > [DA]
  • Increase NA=>Increased euphoria=>Increased motor activity
  • Early drugs e.g. phenelzine & isocarboxazid,
    irreversible and nonselective (Q. Why problem?)
  • Downregulation a2, 5HT1A, b1, b2, 5HT2A, 5HT3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MAO-1

A
  • Associated with food and drug interactions
    • Tyramine (in cheese and wine) acts as indirect sympathomimetic and increased NA release
    • Excess NA destroyed by MAO – if blocked NA will accumulate
    • NA accumulation (Incre headache, intracranial haemorrhage => elevation in BP => severe hypertension)
    • MAOIs not specific – reduce metabolism of opioid analgesics and alcohol
  • Reversible MAOIs (RIMA) e.g. moclobemide
    • Accumulation of NA displaces the RIMA allowing
    degradation of excess NA
    • RIMAs safer and selective RIMAs (e.g moclobemide)
    better tolerated (no major side effects)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

MAOIs Cheese Effect

A
  • MAO in gut is inhibited
  • Dietary amines e.g. tyramine can get into the circulation
  • Foods include cheese, yoghurt, meat, wine, yeast products
  • All contain high concentrations of tyramine
  • Tyramine acts as an indirect sympathomimetic displacing
    noradrenaline from vesicles
17
Q

Tricyclic antidepressant TCAs

A
- Main therapeutic effects:
• NA reuptake inhibitor
• 5-HT reuptake inhibitor
- Initially [NA] & [5-HT] in synaptic cleft
- Chronic treatment down regulation of 
• (β1) & 5-HT2 
- ⍺2, 5-HT1A/1D (autoR)
- Also affect mACh, HR, 5HTR
18
Q

SSRIs (NICE recommendation-less side effects)

A
  • Main therapeutic effects:
    • 5-HT reuptake inhibitor
    • Chronic action: increased [5-HT] down regulation of 5-HT1A/1D autoreceptors, disinhibition of 5-HT neuron,  5-HT release
    • increased 5-HT release down regulatespost synaptic 5-HT receptors ‘normalising’
  • SSRIs safer & better tolerated Why? (but long time to act!)
    • Lack of anticholinergic effect and no cardiotoxicity – better compliance and recommended for long term use
    • Broader therapeutic profile
  • SSRIs generally not as effective as TCAs in severe depression (especially for suicide)
  • Side effects:
    • Insomnia & sexual dysfunction (5-HT2)
    • Nausea; GI distress; headache (5-HT3)
  • Shorter t½ risk of withdrawal effects
  • Increased risk of suicidal behaviour under 18
  • SSRIs may be associated with increased violence (5HT3)
  • Also used for anxiety, GAD and OCD
  • Not used in combination with TCA, MAO-I (inhibits TCA metabolism) (serotonin syndrome/tremor, seizures, hyperthermia, CV collapse)
19
Q

Future development of AD

A
  • Drugs affecting monoamine transmission
    • b3 agonism, D2 agonism/antagonism, 5HT1A antagonism, 5HT2A antagonism with NA/5HT reuptake inhibition
  • Drugs affecting Ion channels
    • nACh agonist, antagonist, partial agonist
    • NMDA blockers (ketamine)
    • AMPA agonists
    • P2X, 5HT receptors, K+ channels
  • Cortisol receptor antagonist, M1/M2 agonist, NK1/NK2 antagonists
20
Q

Problems with AD

A
  • Side effects (especially insomnia=>relapse)
  • Toxic with overdose
  • Delayed effects
  • Non responsive in certain people (30-40% fail to improve with drug treatment)
  • Pharmacogenetics (P450, SERT polymorphisms
    associated with SSRI effectiveness)
  • More efficacious than placebo (BUT some people respond to one type of AD better than others)
21
Q

Bipolar disorder treatment

A

Lithium (Q. for what disorder?)
– Mood stabilizer
– Prophylactic use for depression, acute use mania
– Li+ like Na+ gets into neurons but stays there=> depolarisation
– Mode of action – inhibits enzymes involved in signal transduction
(IP3, phosphorylation, GSK3, hormone induced cAMP inhibition)
– Narrow therapeutic window
– Takes 3-4 weeks to get benefit
– Side effect: drowsiness, confusion, seizures, coma, weight gain, vomiting, renal effect (Na+ imbalance, retention due to increased aldosterone, polyurea), hypothyriodism (monitored)

22
Q

Other treatment of bipolar disorder

A
  • Ion channel blockers
    • Valproate, carbamazepine, topiramate? gabapentine, Pregabalin
  • Antipsychotics (mostly for mania)
    • D2 antagonist, 5HT2A antagonists, other receptors and transporters